European Heart Journal Supplements最新文献

{"title":"The treatment of tricuspid regurgitation.","authors":"Jeroen J Bax","doi":"10.1093/eurheartjsupp/suag053","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suag053","url":null,"abstract":"","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"28 Suppl 4","pages":"iv1"},"PeriodicalIF":1.7,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13128261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focus on tricuspid valve-the European perspective.","authors":"Helge Möllmann, Marcel Weber, Maria Isabel Körber, Theresa Ann-Maria Gößler, Tobias Friedrich Ruf, Hannah Kempton, Paolo Denti, Rodrigo Estevez-Loureiro, Christina Grothusen, Volker Rudolph, Jörg Hausleiter, Holger Thiele","doi":"10.1093/eurheartjsupp/suaf099","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suaf099","url":null,"abstract":"<p><p>Tricuspid regurgitation (TR) affects approximately 4% of individuals over 75 years of age and is associated with substantial morbidity due to heart failure symptoms and frequent hospitalization. In Europe, TR prevalence is expected to rise with an ageing population, contributing to a growing burden on heart failure services. Surgical repair or replacement for isolated TR has been historically underutilized because of high operative risk, however, recent advancements in transcatheter technology have shifted the treatment paradigm. Having once been labelled the forgotten valve, the European interventional cardiology community was suddenly confronted with a number of different devices, all designed to target TR. Having the intrahospital mortality for isolated tricuspid valve surgery in mind, ranging from 8.0% to 12.3%, the initial results of transcatheter therapies with an all-cause mortality of 3.7% at 30 days were promising, although procedural success was achieved in only 62% and cardiac and cerebrovascular major adverse events were as high as 26%. Already, T-TEER constituted the majority of interventions, although miskeyed M-TEER devices were used off-label. Other systems, such as Trialign, TriCinch, FORMA, Cardioband, NaviGate, and caval valve implantation were used distinctively less often.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"28 Suppl 4","pages":"iv70-iv82"},"PeriodicalIF":1.7,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13128270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal failure isn't just a nephrologist problem.","authors":"Gennaro Cice","doi":"10.1093/eurheartjsupp/suag038","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suag038","url":null,"abstract":"<p><p>In the collective perception, uraemic patients are often identified as those undergoing dialysis. In reality, however, dialysis patients represent only a small fraction of the total uraemic population. Conservative estimates indicate that one in ten individuals in the industrialized world has some degree of renal dysfunction, meaning that approximately 700 million people are affected [GBD-Chronic Kidney Disease Collaboration. Global, regional, and national burden of Chronic Kidney Disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> 2020;395:709-33]. These figures have rapidly made chronic kidney disease (CKD)-the correct term for renal failure-a global public health issue, owing both to its unsustainable economic burden for healthcare systems and its high mortality rate, estimated at 2.6 million deaths in 2017 [Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D <i>et al.</i> US Renal Data System 2019 annual data report: epidemiology of kidney disease in the United States. <i>Am J Kidney disease</i> 2020;75:S1-S64]. To mitigate the impact of this true epidemic, new strategies must prioritize early detection and prevention. The first step, however, is conceptual: CKD should no longer be regarded as an exclusively nephrological disorder but as a multisystem condition requiring the attention of internists, cardiologists, diabetologists, and general practitioners alike.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"28 Suppl 5","pages":"v87-v90"},"PeriodicalIF":1.7,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First scan, then treat: 10 years of the SCOT-HEART study.","authors":"Francesco Prati, Andrea Giovagnoli, Giulia Paoletti, Michela Ferrari, Flavio Giuseppe Biccirè, Laura Gatto, Paolo Pavone","doi":"10.1093/eurheartjsupp/suag042","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suag042","url":null,"abstract":"<p><p>The widespread use of coronary computed tomography (CT) to exclude significant coronary stenoses and, more broadly, to achieve a more accurate assessment of cardiovascular risk through the evaluation of atherosclerosis has gained momentum in recent years, largely driven by growing criticism of the traditional ischaemia-centred paradigm. The SCOT-HEART studies were among the first large randomized trials to promote the use of coronary CT in patients presenting with angina. The information provided by coronary CT translated into improved clinical outcomes through the adoption of more aggressive medical therapy, particularly lipid-lowering treatment, which was selectively prescribed to patients with evidence of atherosclerosis. The results of the SCOT-HEART 2 primary prevention trial are eagerly awaited and may further influence clinical practice. Finally, photon-counting CT, representing the latest technological advance, together with the application of artificial intelligence-based image analysis algorithms, may constitute an additional step forward in the use of CT imaging.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"28 Suppl 5","pages":"v143-v147"},"PeriodicalIF":1.7,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classification of cardiomyopathies: bringing order to complexity.","authors":"Maria Perotto, Carola Pio Loco Detto Gava, Federico Garoia, Alessandro Folgheraiter, Valentina Allegro, Giulia Grilli, Aldostefano Porcari, Matteo Dal Ferro, Marco Merlo, Gianfranco Sinagra","doi":"10.1093/eurheartjsupp/suag041","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suag041","url":null,"abstract":"<p><p>Cardiomyopathy classification remains challenging due to their extraordinary clinical, morphological, and genetic heterogeneity. As diagnostic technologies evolve, so too must the frameworks by which we conceptualize and communicate these diseases. Since the 2008 ESC morphofunctional classification and the genotype-phenotype integrated MOGE(S) system proposed in 2013, substantial advances in imaging and genetics have prompted a revised 2023 ESC phenotype-first model. The five current phenotypes-dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and non-dilated left ventricular cardiomyopathy (NDLVC)-capture major morphological expressions but display extensive overlap, especially among DCM, ARVC, and NDLVC. This overlap underscores the need for dynamic, multiparametric diagnostic pathways and individualized interpretation.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"28 Suppl 5","pages":"v159-v163"},"PeriodicalIF":1.7,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moderate mitral regurgitation: when to prefer clip over medical therapy.","authors":"Federica Coletti, Myriam Carpenito, Lorenzo Guarino, Valeria Cammalleri, Elisabetta Ricottini, Rosetta Melfi, Simona Mega, Gian Paolo Ussia, Francesco Grigioni","doi":"10.1093/eurheartjsupp/suag037","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suag037","url":null,"abstract":"<p><p>Functional mitral regurgitation (FMR) is common in patients with heart failure (HF) and is associated with an adverse prognosis. Therefore, both ventricular and atrial phenotypes of FMR represent relevant therapeutic targets in clinical practice. Although randomized clinical trials have primarily focused on the treatment of severe FMR, the prognostic implications and management of moderate FMR have emerged as a topic of increasing interest. This review aims to provide an overview of epidemiology, prognosis, and management of moderate FMR, with a focus on the role of pharmacological treatments and emerging percutaneous strategies.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"28 Suppl 5","pages":"v91-v94"},"PeriodicalIF":1.7,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of transcatheter ablation in ischaemic ventricular tachycardia: should we be using it more?","authors":"Stefano Bianchi, Filippo Maria Cauti","doi":"10.1093/eurheartjsupp/suag018","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suag018","url":null,"abstract":"<p><p>Ischaemic ventricular tachycardia (VT) represents a major cause of morbidity and mortality in patients with ischaemic heart disease. Transcatheter ablation has emerged as a complementary therapeutic strategy to implantable cardioverter-defibrillators (ICDs) and antiarrhythmic drug therapy. The efficacy, safety, optimal timing, and cost-effectiveness of catheter ablation justify its current role in patients with ischaemic cardiomyopathy who undergo device-based interventions. Randomized clinical trials, including VANISH, VANISH2, and PARTITA, have demonstrated that early ablation significantly reduces VT recurrence and ICD shocks compared with antiarrhythmic drug therapy alone. First-line ablation in patients with preserved left ventricular systolic function (LVEF >35%) is associated with excellent long-term outcomes and low rates of sudden cardiac death. Recent advances in functional substrate mapping techniques have further improved procedural outcomes. Periprocedural mortality remains low (0.4-5%) and is mainly attributable to early VT recurrence rather than procedural complications. Current evidence supports a broader use of catheter ablation in ischaemic VT, which has historically been confined to high-volume centres, and particularly suggests its adoption as an early or first-line strategy in selected patients.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"28 Suppl 5","pages":"v22-v26"},"PeriodicalIF":1.7,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ESC guidelines 2025 on cardiovascular disease and pregnancy: considerations and future perspectives.","authors":"Eloisa Arbustini, Fausta Beneventi, Antonio Bozzani, Barbara Cattadori, Maria Paola Delmonte, Alessandro Di Toro, Lorenzo Giuliani, Maurizia Grasso, Carlo Pellegrini, Francesca Perotti, Roberto Rordorf, Alexandra Smirnova, Mario Urtis, Alessandra Serio","doi":"10.1093/eurheartjsupp/suag017","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suag017","url":null,"abstract":"<p><p>Pregnancy in women with cardiovascular disease (CVD) represents a distinct clinical condition, as the physiological adaptations of pregnancy may interact with underlying cardiac pathology in variable and sometimes unpredictable ways. Consequently, maternal and foetal risk cannot be assumed <i>a priori</i> and requires structured, patient- and disease-specific assessment. The new ESC guidelines on cardiovascular disease and pregnancy incorporate updated evidence following the 2018 version. The contents span from models of multidisciplinary care (the Pregnancy Heart Team, PHT), pre-pregnancy counselling, and pregnancy-related risk assessment, to novel recommendations that are both shared by all pregnancies in women with CVD and specific to each distinct disease. Due to limited prospective or randomized studies largely prevented by ethical reasons, most recommendations are based on evidence level C. This document provides a concise synthesis of innovations in shared management strategies and disease-specific pathways in pregnancy of women with known CVD. It also acknowledges that not all clinical scenarios can be fully captured by guideline-based recommendations. Beyond guidelines, and primarily because approximately 50% of recommendations are Level C evidence, there is considerable decision-making margin for cardiovascular specialists to adhere recommendations. For rare unpredictable complications/events the limited available evidence does not allow recommendations to be made. Looking to the future, the expectation is that AI, which is already generating data and models of care in pregnancy, can help support widespread access to PHT, both in hospitals equipped with the necessary requirements and remotely to all healthcare facilities serving pregnant women with CVDs.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"28 Suppl 5","pages":"v5-v13"},"PeriodicalIF":1.7,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of acute pulmonary embolism: anticoagulation, fibrinolysis, and thrombectomy compared.","authors":"Giovanna Manzi, Roberto Badagliacca, Silvia Papa, Carmine Dario Vizza","doi":"10.1093/eurheartjsupp/suag050","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suag050","url":null,"abstract":"<p><p>Acute pulmonary embolism represents a major clinical challenge, characterized by a wide spectrum of phenotypic presentations ranging from asymptomatic disease to cardiovascular collapse. Therapeutic management has evolved from a dichotomous paradigm (anticoagulation vs. thrombolysis) to a risk-stratified approach based on early mortality risk and right ventricular function. This article critically reviews current evidence regarding parenteral and oral anticoagulation, systemic thrombolysis, and emerging catheter-directed thrombectomy techniques, in light of the 2019 European Society of Cardiology guidelines and recent clinical trials.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"28 Suppl 5","pages":"v173-v176"},"PeriodicalIF":1.7,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aldosterone synthesis inhibitors in resistant hypertension: the BaxHTN trial.","authors":"Giovanna Gallo, Maurizio Volterrani, Giuliano Tocci, Massimo Volpe","doi":"10.1093/eurheartjsupp/suag049","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suag049","url":null,"abstract":"<p><p>Inhibitors of the renin-angiotensin-aldosterone system remain foundational therapies for arterial hypertension across major international guidelines. Their effectiveness, however, may be partially attenuated by the phenomenon of aldosterone escape, characterized by chronic elevation of adrenal aldosterone due to activation of alternative enzymatic pathways. Mineralocorticoid receptor antagonists are recommended as first-line therapy for resistant hypertension, yet their clinical utility is limited by poor adherence and high discontinuation rates, driven largely by hyperkalaemia and sex hormone-related adverse effects such as gynaecomastia, impotence, and menstrual irregularities. Recent pharmacologic research has focused on alternative strategies for suppressing aldosterone activity, particularly through the development of selective aldosterone synthase inhibitors (ASIs). This approach has led to the emergence of highly selective agents such as baxdrostat and lorundrostat. Clinical studies have demonstrated meaningful reductions in blood pressure among patients with resistant or uncontrolled hypertension, with favourable tolerability and without clinically significant adverse events. Further studies are required to determine the impact of ASIs on hypertensive-mediated organ damage, major cardiovascular events, nephrovascular outcomes, and long-term safety.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"28 Suppl 5","pages":"v177-v180"},"PeriodicalIF":1.7,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}